Nossos produtos são clinicamente testados por terceiros
Leia Mais
×
Experimente resultados com confiança
Se a Hairgenetix não entregar resultados em 4 meses, obtenha um reembolso total em apenas 3 passos simples.
Trusted by hundreds e rated
Com uma classificação 'Excelente' de 4,6 estrelas, baseada em mais de 1.200 avaliações, a confiança dos nossos clientes no Hairgenetix reflete os resultados notáveis que você pode alcançar com nossos produtos de crescimento capilar.
Nossos produtos são clinicamente testados por terceiros
Em um ensaio clínico de 150 dias envolvendo 30 homens e mulheres de 18 a 65 anos com diversos tipos de queda de cabelo, o sérum Hairgenetix alcançou uma redução clinicamente comprovada de 93% na queda de cabelo.
Publicado por Ruri D. Pamela em 05 de March de 2026
Key Findings at a Glance
Copper tripeptide serum improved crescimento capilar: The active tratamento group (copper tripeptide + Swertia japonica serum com nano-fractional radiofrequency) showed 26–50% improvement versus 0–25% in o placebo group
Safe e well-tolerated: No serious adverse events; only one report of mild couro cabeludo itching in o active group across o entire 6-month trial
Combined delivery approach: First study to test copper tripeptide serum delivered via nano-fractional radiofrequency para male pattern queda de cabelo
Pilot-scale evidence: This was a small proof-of-concept study (6 patients) — o resultados são promising but need confirmation in larger trials
All patients completed tratamento: 100% retention across both groups over 6 months, suggesting excellent tolerability
Evidence Summary
Study Design
Randomised, single-blind, placebo-controlled comparative study
Sample Size
6 men (3 active tratamento, 3 placebo)
Duration
6 months com monthly sessions
Key Result
Active group: 26–50% improvement (Scale 1) vs placebo: 0–25% improvement (Scale 0)
Evidence Level
Level 4 — Pilot study / case series (very small sample)
Medical Disclaimer: This article summarises published pesquisa clínica para educational purposes only. It is not medical advice. This was a small pilot study (6 participants) — resultados são preliminary e require confirmation in larger trials. Always consult a qualified healthcare professional antes starting any queda de cabelo tratamento.
Reviewed by: Esther Bodde, MD — Physician e medical content reviewer at Hairgenetix. Dr. Bodde ensures all pesquisa clínica summaries accurately represent o original study data, methodology, e conclusions. Note: This study has notable limitations due to its very small sample size, which são discussed transparently in o Limitations section below.
Why This Research Matters
Most peptídeo de cobre research has focused on GHK-Cu (glycyl-L-histidyl-L-lysine copper) in laboratory settings — studying its effects on isolated folículo capilars or reviewing its gene expression profile. What has been missing is pesquisa clínica testing whether topical copper tripeptide serums actually improve crescimento capilar in real patients.
This 2021 pilot study by Ruri D. Pamela addresses que gap. It is one of o first estudos clínicos to test a copper tripeptide-containing serum in men com pattern queda de cabelo, using a proper placebo-controlled design. While o sample is small (6 patients), it represents an important step in o evidence chain: moving de laboratory proof-of-concept to human clinical testing.
The study also introduces an innovative delivery approach — using nano-fractional radiofrequency to create micro-channels in o couro cabeludo antes applying o copper tripeptide serum. This builds on o same principle que makes microagulhamento so eficaz para crescimento capilar: physical couro cabeludo stimulation combined com enhanced topical absorption produces better resultados than either approach alone.
What The Researchers Did
The researcher recruited 6 men aged 35–65 com moderate to severe male pattern queda de cabelo (Hamilton-Norwood Scale IV to VI). These men were randomly assigned to one of two groups:
Both groups received o same radiofrequency tratamento — o only difference was what was applied to o couro cabeludo afterwards. The investigator who assessed resultados de photographs was blinded (did not know which group each patient was in), adding objectivity to o evaluation.
What Is a Randomised Single-Blind Placebo-Controlled Study?
This study design gives researchers confidence que any improvement is due to o tratamento, not other factors. Patients são randomly assigned to groups (randomised), o person assessing resultados doesn't know who got what (single-blind), e o comparison group receives a dummy tratamento (placebo-controlled). This é um strong study design — though com only 6 participants, o statistical power is very limited. Think of it as a well-designed experiment que needs to be repeated on a much larger scale to confirm o findings.
What They Found
1. Investigator-assessed improvement
Finding: The blinded investigator assessed o active tratamento group as showing Scale 1 improvement (26–50% improvement) at o final visit, while o placebo group showed Scale 0 improvement (0–25%).
The investigator compared standardised photographs taken at baseline e at 6 months. The active group showed visually noticeable improvement que o blinded evaluator rated as meaningful, while o placebo group (same radiofrequency, saline instead of serum) showed minimal change.
2. Trichoscopic observations
Finding: At baseline, trichoscopy revealed classic signs of androgenetic alopecia in both groups: hair diameter diversity (hairs of very different thicknesses), perifollicular pigmentation (brown halos around follicles), e yellow dots (empty follicle openings filled com sebum). The active group showed improvement in these markers over o tratamento period.
3. Safety e tolerability
Finding:No serious adverse events were reported in either group. The only adverse event was one case of mild couro cabeludo itching in o active tratamento group. All 6 patients completed o full 6-month tratamento course — a 100% retention rate.
The excellent tolerability is notable. Six months of monthly radiofrequency tratamentos com topical serum application produced essentially no efeitos colaterais, suggesting este approach is well-suited para long-term maintenance therapy.
Figure 1. Key outcomes de Pamela (2021) — copper tripeptide serum + nano-fractional radiofrequency vs placebo over 6 months. Data source: J Clin Exp Dermatol Res, Vol. 12, Article 590.
How This Treatment Works: The Science Behind o Combination
1. Copper tripeptide — follicle stimulation e protection
Copper tripeptide (GHK-Cu) is one of o most studied peptides in regenerative medicine. Research shows it affects 31.2% of human genes, upregulating genes involved in tissue repair, collagen synthesis, e blood vessel formation while downregulating inflammatory e tissue-destructive genes. In hair specifically, o AHK-Cu study (2007) demonstrated que peptídeo de cobres promote folículo capilar elongation e protect follicular cells de premature death (apoptosis).
2. Swertia japonica extract — anti-inflammatory e antioxidant support
Swertia japonica é um plant used in traditional Japanese medicine. The extract contains bioactive compounds com anti-inflammatory e antioxidant properties, which may help create a healthier couro cabeludo environment para crescimento capilar. Couro cabeludo inflammation is increasingly recognised as a factor in androgenetic alopecia progression.
3. Nano-fractional radiofrequency — enhanced delivery e stimulation
The Venus Viva® device entrega radiofrequency energy através de tiny pin-like electrodes, creating controlled micro-injuries similar to microagulhamento but com o added benefit of thermal energy. This serves a dual purpose: it triggers o wound healing cascade (releasing fatores de crescimento like PDGF, VEGF, e FGF) while simultaneously creating micro-channels que enhance serum absorption. This delivery principle is o same one que makes microagulhamento + topical combinations so eficaz.
Putting o Results in Context
The improvement seen in o active group (26–50% on o investigator scale) over 6 months is encouraging, but context is essential:
The improvement level is broadly comparable to other peptídeo de cobre studies, though direct comparison is difficult because este study used a categorical improvement scale rather than exact hair counts. The 6-month duration e monthly sessions make it a less intensive protocol than weekly microagulhamento regimens.
Key limitation: With only 3 patients per group, even a single unusually responsive or non-responsive patient could substantially skew o resultados. The findings should be interpreted as promising preliminary evidence, not definitive proof.
How This Study Fits in o Peptídeo de Cobre Evidence Base
26.5% improvement com microagulhamento + peptídeo de cobre combination
This study adds a unique piece to o peptídeo de cobre puzzle: it demonstrates o concept of using energy-based devices (radiofrequency) to deliver peptídeo de cobre serums, rather than relying on simple topical application. The principle is o same as microagulhamento — physical couro cabeludo stimulation + enhanced ingredient absorption — but using a different technology.
Treatment Protocol Used in This Study
Parameter
Specification
Device
Venus Viva® nano-fractional radiofrequency
Active serum
Copper tripeptide + Swertia japonica extract
Placebo
Normal saline (0.9% NaCl)
Application
Serum applied immediately após radiofrequency tratamento
Session frequency
Monthly (once per month)
Total duration
6 months (6 sessions)
Patient population
Men aged 35–65, Hamilton-Norwood IV–VI
Setting
Clinical
Note: Venus Viva® é um professional-grade device used in clinical settings. The principle of enhanced topical absorption can also be achieved através de microagulhamento, which is more widely available. The key insight de este study is o combination approach: physical couro cabeludo stimulation followed by peptídeo de cobre serum application.
Research Limitations
Very small sample size: With only 6 patients total (3 per group), este study has extremely limited statistical power. Results could be substantially influenced by individual variation. This is o most significant limitation
No statistical significance testing: The paper does not report p-values or statistical tests. With n=3 per group, meaningful statistical analysis is not possible
Categorical outcome scale: Results were reported as improvement categories (0–25%, 26–50%) rather than exact hair counts or measurements, making precise comparison com other studies difficult
Industry funding: The study was funded by Highside Corp. (Tokyo, Japan), which may have a commercial interest in o serum product. This does not invalidate o findings but adds a potential source of bias
Single-blind only: While o investigator assessing photos was blinded, patients knew whether they received o active serum or saline, which could influence self-reported satisfaction scores
No long-term follow-up: The study ended at 6 months. Whether improvements são maintained após tratamento cessation is unknown
Moderate-to-severe cases only: Participants had Hamilton-Norwood IV–VI, representing more advanced queda de cabelo. Results may differ para earlier-stage patients
Combined tratamento effect: Both groups received radiofrequency, so o study measures o added effect of o serum — not o serum alone. It cannot separate o contributions of copper tripeptide e Swertia japonica individually
What This Means para Your Hair
This pilot study adds to o growing body of evidence que combining peptídeo de cobre application com physical couro cabeludo stimulation is more eficaz than either approach alone. While o sample size is too small para definitive conclusions, o resultados são consistent com what larger studies have found:
The Kuceki et al. 2025 study found similar improvement levels (26.5%) when combining peptídeo de cobres com microagulhamento
The Dhurat 2013 landmark study established que physical couro cabeludo stimulation + topical tratamento dramatically outperforms topical tratamento alone
The practical takeaway: You do not necessarily need a Venus Viva® device to benefit de este principle. The combination of microagulhamento (which is widely available e extensively studied) com a peptídeo de cobre serum works através de o same mechanisms: creating micro-channels para enhanced absorption while triggering o body's wound healing response. The key is choosing a peptídeo de cobre formulation com proven bioingredientes ativos e applying it após couro cabeludo stimulation to maximise absorption.
Key Terms Explained
Copper Tripeptide (GHK-Cu)
A small peptide (three amino acids: glycine, histidine, lysine) naturally bound to copper. It occurs naturally in human plasma e declines com age. Research shows it estimula produção de colágeno, promove tissue repair, e activates genes involved in folículo capilar growth.
Nano-Fractional Radiofrequency
A technology que entrega radiofrequency energy através de tiny pin-like electrodes to create controlled micro-injuries in o skin. Unlike traditional microagulhamento (which uses physical needles), it combines mechanical disruption com thermal energy. The Venus Viva® device used in este study is one commercial system para este approach.
Swertia japonica
A plant de o gentian family used in traditional Japanese medicine. Its extract contains bioactive compounds com anti-inflammatory e antioxidant properties. In este study, it was combined com copper tripeptide to create o active serum formulation.
Hamilton-Norwood Scale
A classification system (grades I to VII) used to measure o severity of male pattern queda de cabelo. This study included grades IV to VI, representing moderate to severe queda de cabelo com significant crown thinning e frontal recession.
Placebo-Controlled
A study design where one group receives o actual tratamento while another receives an inactive substitute (placebo). In este study, o placebo was normal saline (salt water) applied após o same radiofrequency procedure, allowing researchers to isolate o effect of o active serum ingredientes.
Trichoscopy
A non-invasive diagnostic technique using a specialised microscope (dermoscope) to examine o couro cabeludo e hair at high magnification. It reveals features invisible to o naked eye, such as hair diameter variation, follicular condition, e inflammation markers.
Perifollicular Pigmentation (Peripilar Sign)
A brown or dark halo visible around folículo capilars under trichoscopy. It indicates mild inflammation around o follicle e is commonly seen in androgenetic alopecia. Its presence or reduction can indicate tratamento response.
Single-Blind Study
A study design where one party (typically o evaluator) does not know which tratamento each participant received. In este study, o investigator assessing photographs was blinded, but patients knew whether they received o active serum or saline.
Frequently Asked Questions
How reliable são resultados de a study com only 6 patients?
Very limited. A study com 6 participants (3 per group) is considered a pilot study — it demonstrates que a concept is worth investigating further, but cannot prove que a tratamento works. With so few patients, one unusually responsive individual could skew o entire result. Think of it as a promising early signal, not a proven conclusion. The resultados become meaningful when viewed alongside larger studies on peptídeo de cobres e physical couro cabeludo stimulation que show consistent positive effects.
What is nano-fractional radiofrequency, e how is it different de microagulhamento?
Both create controlled micro-injuries in o couro cabeludo, but they use different mechanisms. Microagulhamento uses physical needles (typically 0.25–1.5 mm) to puncture o skin. Nano-fractional radiofrequency uses tiny electrodes que deliver heat energy, creating micro-injuries através de thermal ablation. The end result is similar: channels para topical absorption, growth factor release, e wound healing response. Microagulhamento is more widely available, more extensively studied para queda de cabelo, e can be done at home (with shorter needles). Radiofrequency devices like Venus Viva® são clinical-grade only.
Can I get o same benefit using microagulhamento com a peptídeo de cobre serum instead?
Likely yes. The underlying principle — physical couro cabeludo stimulation + peptídeo de cobre delivery — is o same regardless of whether você use microagulhamento or radiofrequency. In fact, microagulhamento has a larger evidence base para crescimento capilar than radiofrequency. The Kuceki 2025 study demonstrated significant resultados (26.5% improvement) using microagulhamento combined com peptídeo de cobre serums, e o Gupta 2022 meta-analysis confirmed microagulhamento's efficacy across multiple studies.
What is Swertia japonica, e does it contribute to crescimento capilar?
Swertia japonica é um plant used in traditional Japanese e Chinese medicine. The extract has documented anti-inflammatory e antioxidant properties. While there is limited research on its specific effects on crescimento capilar, couro cabeludo inflammation é um known contributing factor in androgenetic alopecia. The anti-inflammatory properties may help create a healthier couro cabeludo environment. However, since este study combined Swertia japonica com copper tripeptide, it is impossible to determine how much each ingredient contributed independently.
Is este o same as o GHK-Cu used in other peptídeo de cobre studies?
"Copper tripeptide" e "GHK-Cu" both refer to o same molecule: glycyl-L-histidyl-L-lysine bound to a copper ion. The Pickart & Margolina 2018 review documented its extensive gene-modulating effects, e o AHK-Cu 2007 study tested a related variant on folículo capilars in o lab. This study tests it in actual patients para o first time in combination com radiofrequency delivery.
Should I wait para larger studies antes trying peptídeo de cobre serums?
That é um personal decision. The safety data is reassuring — peptídeo de cobres have shown excellent tolerability across all studies, com no serious adverse effects. The efficacy evidence is growing: lab studies (AHK-Cu 2007), a 45-patient RCT (Lee/Kim 2016), combination studies (Kuceki 2025), e now este pilot study all point in o same direction. Waiting para a single "definitive" large trial may mean missing years of potential benefit de an ingredient com a strong safety profile.
Why was o study funded by a company?
Industry-funded research is common in dermatology e cosmetic science. Highside Corp. (Tokyo, Japan) funded este study, which means they had a potential commercial interest in positive resultados. This does not automatically invalidate o findings, but it is important context. The study's single-blind design e placebo control add credibility, but o very small sample size means o resultados should be interpreted cautiously. Independent replication in a larger, independently funded trial would significativamente strengthen o evidence.
What Hamilton-Norwood stages were included, e do resultados vary by severity?
Patients had Hamilton-Norwood stages IV to VI — representing moderate to severe queda de cabelo. This is notable because more advanced queda de cabelo is generally harder to treat (more follicles may be permanently miniaturised). The fact que improvement was observed even at these stages is encouraging. Earlier-stage patients (NW II–III) might potentially see even better resultados, though este has not been tested para este specific combination. The Dhurat 2013 study included NW III–IV patients e saw strong resultados.
Original Study Citation
Pamela RD. Evaluation Efficacy of Topically Applied Serum Containing Copper Tripeptide e Swertia Japonica Extract in Male Pattern Baldness: A Placebo-Controlled Case Study. Journal of Clinical & Experimental Dermatology Research. 2021;12:590. Available at: longdom.org.
How to cite este summary:
Hairgenetix Research Hub. "Copper Tripeptide Serum para Queda de Cabelo: A Placebo-Controlled Clinical Study (2021) — A Plain-Language Summary of Pamela (2021)." Hairgenetix, 2025. Available at: https://hairgenetix.com/blogs/articles/copper-tripeptide-serum-hair-loss-clinical-study-2021
Last updated: March 2026 — Reviewed para accuracy against o original publication. Cross-references updated to include 2024 e 2025 studies.
About Hairgenetix Research Hub — Hairgenetix translates peer-reviewed hair science em plain-language summaries so você can make informed decisions sobre seu cuidado capilar. Every article is based on published pesquisa clínica, reviewed by a physician (Dr. Esther Bodde, MD), e includes direct links to o original studies. We present research transparently — including study limitations — because informed consumers make better decisions. Our peptídeo de cobre formulations são grounded in o same GHK-Cu science documented across este e related estudos clínicos.
Terapia Capilar Diária Avançada para Cabelos Mais Fortes e Saudáveis
🎯 Desenvolvido para queda de cabelo e cabelos fracos e ralos
🔬 Ingredientes Clinicamente Comprovados
💧 Leve, não oleoso — ideal para uso diário
O Sérum de Peptídeo de Cobre Hairgenetix é um tratamento capilar diário poderoso, desenvolvido para estimular os folículos capilares, reduzir a queda e promover a saúde capilar a longo prazo. Enriquecido com 10% de GHK-Cu e 5% de AHK-Cu peptídeos de cobre, esta fórmula avançada age na raiz para melhorar a longevidade dos folículos, estimular a produção de colágeno e melhorar a circulação no couro cabeludo — criando o ambiente perfeito para um crescimento capilar mais espesso e saudável.
Shampoo com Peptídeo de Cobre para Crescimento Capilar
O Shampoo Hairgenetix com GHK-Cu limpa suavemente enquanto entrega peptídeos de cobre diretamente no couro cabeludo. Formulado para estimular os folículos capilares e criar o ambiente ideal para crescimento capilar saudável. Uso diário recomendado.
Condicionador com Peptídeo de Cobre para Crescimento Capilar
O Condicionador Hairgenetix com GHK-Cu oferece hidratação profunda enquanto entrega peptídeos de cobre. Fortalece os fios, reduz a quebra e estimula o crescimento capilar saudável. Complemento perfeito para o Shampoo Hairgenetix.
O Kit completo Hairgenetix com Shampoo e Condicionador de Peptídeo de Cobre GHK-Cu. Limpeza suave + hidratação profunda + peptídeos de cobre para crescimento capilar otimizado. Economize comprando o kit.
Kit Completo Peptídeo de Cobre — Shampoo, Condicionador e Sérum
O tratamento capilar completo com peptídeo de cobre: Shampoo GHK-Cu + Condicionador GHK-Cu + Sérum de Peptídeo de Cobre. Tudo que você precisa para uma rotina capilar completa com peptídeos de cobre clinicamente comprovados.
Estudo Clínico do Tripeptídeo de Cobre (2021)
Why This Research Matters
Most peptídeo de cobre research has focused on GHK-Cu (glycyl-L-histidyl-L-lysine copper) in laboratory settings — studying its effects on isolated folículo capilars or reviewing its gene expression profile. What has been missing is pesquisa clínica testing whether topical copper tripeptide serums actually improve crescimento capilar in real patients.
This 2021 pilot study by Ruri D. Pamela addresses que gap. It is one of o first estudos clínicos to test a copper tripeptide-containing serum in men com pattern queda de cabelo, using a proper placebo-controlled design. While o sample is small (6 patients), it represents an important step in o evidence chain: moving de laboratory proof-of-concept to human clinical testing.
The study also introduces an innovative delivery approach — using nano-fractional radiofrequency to create micro-channels in o couro cabeludo antes applying o copper tripeptide serum. This builds on o same principle que makes microagulhamento so eficaz para crescimento capilar: physical couro cabeludo stimulation combined com enhanced topical absorption produces better resultados than either approach alone.
What The Researchers Did
The researcher recruited 6 men aged 35–65 com moderate to severe male pattern queda de cabelo (Hamilton-Norwood Scale IV to VI). These men were randomly assigned to one of two groups:
Both groups received o same radiofrequency tratamento — o only difference was what was applied to o couro cabeludo afterwards. The investigator who assessed resultados de photographs was blinded (did not know which group each patient was in), adding objectivity to o evaluation.
This study design gives researchers confidence que any improvement is due to o tratamento, not other factors. Patients são randomly assigned to groups (randomised), o person assessing resultados doesn't know who got what (single-blind), e o comparison group receives a dummy tratamento (placebo-controlled). This é um strong study design — though com only 6 participants, o statistical power is very limited. Think of it as a well-designed experiment que needs to be repeated on a much larger scale to confirm o findings.
What They Found
1. Investigator-assessed improvement
The investigator compared standardised photographs taken at baseline e at 6 months. The active group showed visually noticeable improvement que o blinded evaluator rated as meaningful, while o placebo group (same radiofrequency, saline instead of serum) showed minimal change.
2. Trichoscopic observations
3. Safety e tolerability
The excellent tolerability is notable. Six months of monthly radiofrequency tratamentos com topical serum application produced essentially no efeitos colaterais, suggesting este approach is well-suited para long-term maintenance therapy.
How This Treatment Works: The Science Behind o Combination
1. Copper tripeptide — follicle stimulation e protection
Copper tripeptide (GHK-Cu) is one of o most studied peptides in regenerative medicine. Research shows it affects 31.2% of human genes, upregulating genes involved in tissue repair, collagen synthesis, e blood vessel formation while downregulating inflammatory e tissue-destructive genes. In hair specifically, o AHK-Cu study (2007) demonstrated que peptídeo de cobres promote folículo capilar elongation e protect follicular cells de premature death (apoptosis).
2. Swertia japonica extract — anti-inflammatory e antioxidant support
Swertia japonica é um plant used in traditional Japanese medicine. The extract contains bioactive compounds com anti-inflammatory e antioxidant properties, which may help create a healthier couro cabeludo environment para crescimento capilar. Couro cabeludo inflammation is increasingly recognised as a factor in androgenetic alopecia progression.
3. Nano-fractional radiofrequency — enhanced delivery e stimulation
The Venus Viva® device entrega radiofrequency energy através de tiny pin-like electrodes, creating controlled micro-injuries similar to microagulhamento but com o added benefit of thermal energy. This serves a dual purpose: it triggers o wound healing cascade (releasing fatores de crescimento like PDGF, VEGF, e FGF) while simultaneously creating micro-channels que enhance serum absorption. This delivery principle is o same one que makes microagulhamento + topical combinations so eficaz.
Putting o Results in Context
The improvement seen in o active group (26–50% on o investigator scale) over 6 months is encouraging, but context is essential:
The improvement level is broadly comparable to other peptídeo de cobre studies, though direct comparison is difficult because este study used a categorical improvement scale rather than exact hair counts. The 6-month duration e monthly sessions make it a less intensive protocol than weekly microagulhamento regimens.
Key limitation: With only 3 patients per group, even a single unusually responsive or non-responsive patient could substantially skew o resultados. The findings should be interpreted as promising preliminary evidence, not definitive proof.
How This Study Fits in o Peptídeo de Cobre Evidence Base
This study adds a unique piece to o peptídeo de cobre puzzle: it demonstrates o concept of using energy-based devices (radiofrequency) to deliver peptídeo de cobre serums, rather than relying on simple topical application. The principle is o same as microagulhamento — physical couro cabeludo stimulation + enhanced ingredient absorption — but using a different technology.
Note: Venus Viva® é um professional-grade device used in clinical settings. The principle of enhanced topical absorption can also be achieved através de microagulhamento, which is more widely available. The key insight de este study is o combination approach: physical couro cabeludo stimulation followed by peptídeo de cobre serum application.
Research Limitations
What This Means para Your Hair
This pilot study adds to o growing body of evidence que combining peptídeo de cobre application com physical couro cabeludo stimulation is more eficaz than either approach alone. While o sample size is too small para definitive conclusions, o resultados são consistent com what larger studies have found:
The practical takeaway: You do not necessarily need a Venus Viva® device to benefit de este principle. The combination of microagulhamento (which is widely available e extensively studied) com a peptídeo de cobre serum works através de o same mechanisms: creating micro-channels para enhanced absorption while triggering o body's wound healing response. The key is choosing a peptídeo de cobre formulation com proven bioingredientes ativos e applying it após couro cabeludo stimulation to maximise absorption.
Key Terms Explained
Frequently Asked Questions
How reliable são resultados de a study com only 6 patients?
Very limited. A study com 6 participants (3 per group) is considered a pilot study — it demonstrates que a concept is worth investigating further, but cannot prove que a tratamento works. With so few patients, one unusually responsive individual could skew o entire result. Think of it as a promising early signal, not a proven conclusion. The resultados become meaningful when viewed alongside larger studies on peptídeo de cobres e physical couro cabeludo stimulation que show consistent positive effects.
What is nano-fractional radiofrequency, e how is it different de microagulhamento?
Both create controlled micro-injuries in o couro cabeludo, but they use different mechanisms. Microagulhamento uses physical needles (typically 0.25–1.5 mm) to puncture o skin. Nano-fractional radiofrequency uses tiny electrodes que deliver heat energy, creating micro-injuries através de thermal ablation. The end result is similar: channels para topical absorption, growth factor release, e wound healing response. Microagulhamento is more widely available, more extensively studied para queda de cabelo, e can be done at home (with shorter needles). Radiofrequency devices like Venus Viva® são clinical-grade only.
Can I get o same benefit using microagulhamento com a peptídeo de cobre serum instead?
Likely yes. The underlying principle — physical couro cabeludo stimulation + peptídeo de cobre delivery — is o same regardless of whether você use microagulhamento or radiofrequency. In fact, microagulhamento has a larger evidence base para crescimento capilar than radiofrequency. The Kuceki 2025 study demonstrated significant resultados (26.5% improvement) using microagulhamento combined com peptídeo de cobre serums, e o Gupta 2022 meta-analysis confirmed microagulhamento's efficacy across multiple studies.
What is Swertia japonica, e does it contribute to crescimento capilar?
Swertia japonica é um plant used in traditional Japanese e Chinese medicine. The extract has documented anti-inflammatory e antioxidant properties. While there is limited research on its specific effects on crescimento capilar, couro cabeludo inflammation é um known contributing factor in androgenetic alopecia. The anti-inflammatory properties may help create a healthier couro cabeludo environment. However, since este study combined Swertia japonica com copper tripeptide, it is impossible to determine how much each ingredient contributed independently.
Is este o same as o GHK-Cu used in other peptídeo de cobre studies?
"Copper tripeptide" e "GHK-Cu" both refer to o same molecule: glycyl-L-histidyl-L-lysine bound to a copper ion. The Pickart & Margolina 2018 review documented its extensive gene-modulating effects, e o AHK-Cu 2007 study tested a related variant on folículo capilars in o lab. This study tests it in actual patients para o first time in combination com radiofrequency delivery.
Should I wait para larger studies antes trying peptídeo de cobre serums?
That é um personal decision. The safety data is reassuring — peptídeo de cobres have shown excellent tolerability across all studies, com no serious adverse effects. The efficacy evidence is growing: lab studies (AHK-Cu 2007), a 45-patient RCT (Lee/Kim 2016), combination studies (Kuceki 2025), e now este pilot study all point in o same direction. Waiting para a single "definitive" large trial may mean missing years of potential benefit de an ingredient com a strong safety profile.
Why was o study funded by a company?
Industry-funded research is common in dermatology e cosmetic science. Highside Corp. (Tokyo, Japan) funded este study, which means they had a potential commercial interest in positive resultados. This does not automatically invalidate o findings, but it is important context. The study's single-blind design e placebo control add credibility, but o very small sample size means o resultados should be interpreted cautiously. Independent replication in a larger, independently funded trial would significativamente strengthen o evidence.
What Hamilton-Norwood stages were included, e do resultados vary by severity?
Patients had Hamilton-Norwood stages IV to VI — representing moderate to severe queda de cabelo. This is notable because more advanced queda de cabelo is generally harder to treat (more follicles may be permanently miniaturised). The fact que improvement was observed even at these stages is encouraging. Earlier-stage patients (NW II–III) might potentially see even better resultados, though este has not been tested para este specific combination. The Dhurat 2013 study included NW III–IV patients e saw strong resultados.
Pamela RD. Evaluation Efficacy of Topically Applied Serum Containing Copper Tripeptide e Swertia Japonica Extract in Male Pattern Baldness: A Placebo-Controlled Case Study. Journal of Clinical & Experimental Dermatology Research. 2021;12:590. Available at: longdom.org.
Hairgenetix Research Hub. "Copper Tripeptide Serum para Queda de Cabelo: A Placebo-Controlled Clinical Study (2021) — A Plain-Language Summary of Pamela (2021)." Hairgenetix, 2025. Available at: https://hairgenetix.com/blogs/articles/copper-tripeptide-serum-hair-loss-clinical-study-2021